Your browser doesn't support javascript.
loading
Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm.
Liu, Yongbin; Yu, Dongfang; Ge, Xueying; Huang, Lingyi; Pan, Ping-Ying; Shen, Haifa; Pettigrew, Roderic I; Chen, Shu-Hsia; Mai, Junhua.
Affiliation
  • Liu Y; Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA. Electronic address: yliu2@houstonmethodist.org.
  • Yu D; Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA.
  • Ge X; School of Engineering Medicine/ENMED, Texas A&M University and Houston Methodist Hospital, Houston, TX, 77030, USA.
  • Huang L; Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA.
  • Pan PY; Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX, 77030, USA.
  • Shen H; Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA.
  • Pettigrew RI; School of Engineering Medicine/ENMED, Texas A&M University and Houston Methodist Hospital, Houston, TX, 77030, USA.
  • Chen SH; Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX, 77030, USA; Weill Cornell Medical College, New York, NY, 10065, USA. Electronic address: schen3@houstonmethodist.org.
  • Mai J; Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA. Electronic address: jmai@houstonmethodist.org.
Biomaterials ; 314: 122835, 2024 Sep 11.
Article in En | MEDLINE | ID: mdl-39276409
ABSTRACT
Induction of reactive oxygen species (ROS) production in cancer cells plays a critical role for cancer treatment. However, therapeutic efficiency remains challenging due to insufficient ROS production of current ROS inducers. We designed a novel platinum (Pt)-based drug named "carrier-platin" that integrates ultrasmall Pt-based nanoparticles uniformly confined within a poly(amino acids) carrier. Carrier-platin dramatically triggered a burst of ROS in cancer cells, leading to cancer cell death as quick as 30 min. Unlike traditional Pt-based drugs which induce cell apoptosis through DNA intercalation, carrier-platin with superior ROS catalytic activities induces a unique pattern of cancer cell death that is neither apoptosis nor ferroptosis and operates independently of DNA damage. Importantly, carrier-platin demonstrates superior anti-tumor efficacy against a broad spectrum of cancers, particularly those with multidrug resistance, while maintaining minimal systemic toxicity. Our findings reveal a distinct mechanism of action of Pt in cancer cell eradication, positioning carrier-platin as a novel category of anti-cancer chemotherapeutics.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomaterials Year: 2024 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Biomaterials Year: 2024 Document type: Article Country of publication: Netherlands